Comparison of the Effects of Propofol and Midazolam on Inflammation and Oxidase Stress in Children with Congenital Heart Disease Undergoing Cardiac Surgery by Xia, Wen-fang et al.
Yonsei Med J   http://www.eymj.org   Volume 52   Number 2   March 2011 326
Original Article
DOI 10.3349/ymj.2011.52.2.326
pISSN: 0513-5796, eISSN: 1976-2437       Yonsei Med J 52(2):326-332, 2011
Comparison of the Effects of Propofol and Midazolam on 
Inflammation and Oxidase Stress in Children with  
Congenital Heart Disease Undergoing Cardiac Surgery
Wen-fang Xia,
1,2* Yu Liu,
2,3* Qing-shan Zhou,
1 Qi-zhu Tang,
2,3 and Han-dong Zou
1
Departments of 1Critic Care Medicine and 2Cardiology, Renmin Hospital of Wuhan University, Wuhan;
3Cardiovascular Research Institute, Wuhan University, Wuhan, P.R. China.
Received: June 9, 2010
Revised: August 24, 2010
Accepted: September 9, 2010
Co-corresponding authors: Dr. Qing-shan Zhou,
Department of Critic Care Medicine, Renmin 
Hospital of Wuhan University, 238 Jiefang 
Road, Wuhan 430060, P.R. China. 
Tel: 86 27 88041911, Fax: 86 27 88041911
E-mail: zhouqingshan2010@yahoo.com.cn
and Dr. Qi-zhu Tang,
Department of Cardiology, Renmin Hospital of 
Wuhan University, 238 Jiefang Road, Wuhan 
430060, P.R. China.
Tel: 86 27 88042922, Fax: 86 27 88042922
E-mail: qztang@whu.edu.cn
*These authors contributed equally to this 
work.
∙ The authors have no financial conflicts of 
interest.
© Copyright:
Yonsei University College of Medicine 2011
This is an Open Access article distributed under the 
terms of the Creative Commons Attribution Non-
Commercial License (http://creativecommons.org/ 
licenses/by-nc/3.0) which permits unrestricted non-
commercial use, distribution, and reproduction in any 
medium, provided the original work is properly cited.
Purpose: To investigate and compare the effects of propofol and midazolam on in-
flammation and oxidase stress in children with congenital heart disease undergo-
ing cardiac surgery. Materials and Methods: Thirty-two ASA class I-II children 
with congenital heart disease undergoing cardiac surgery were randomly divided 
into two groups: propofol combined with low dose fentanyl (PF group, n = 16) 
and midazolam combined with low dose fentanyl (MF group, n = 16). Tracheal 
extubation time and length of Intensive Care Unit (ICU) stay were recorded. 
Blood samples were taken before operation (T0), at 2 h after release of the aorta 
cross-clamp (T3) and at 24 h after operation (T4) to measure interleukin 6 (IL-6), 
IL-8, superoxide dismutase (SOD) and malondialdehyde (MDA) levels. Myocar-
dium samples were collected at 10-20 min after aorta cross-clamp (T1) and at 10-
20 min after the release of the aorta cross-clamp (T2) to detect heme oxygenase-1 
(HO-1) expression. Results: Tracheal extubation time and length of ICU stay in 
PF group were significantly shorter than those of the MF group (p < 0.05, respec-
tively). After cardiopulmonary bypass, IL-6, IL-8 and MDA levels were signifi-
cantly increased, and the SOD level was significantly reduced in both two groups, 
but PF group exhibited lower IL-6, IL-8 and MDA levels and higher SOD levels 
than the MF group (p < 0.05, respectively). The HO-1 expression in the PF group 
was significantly higher than that in MF group at the corresponding time points (p 
< 0.05, respectively). Conclusion: Propofol is superior to midazolam in reducing 
inflammation and oxidase stress and in improving post-operation recovery in chil-
dren with congenital heart disease undergoing cardiac surgery.
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INTRODUCTION
Congenital heart disease is the most common of all congenital malformations, 
with a high incidence of 6 to 8 per 1,000 live births. Despite major advances in de-
tection and treatment, congenital heart disease accounts for 3% of all infant deaths 
and 46% of deaths due to congenital malformations.1Propofol and Midazolam in Cardiac Surgery
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and pre-operative use of anti-inflammatory and/or anti-oxi-
dant drugs were excluded.
Anesthesia
Thirty minutes before entering the operating room, all pa-
tients were given morphine (0.1 mg/kg) and scopolamine 
(0.01 mg/kg) by intramuscular injection. In the PF group, 
anesthesia induction was induced by intravenous injection 
of propofol (1 mg/kg), fentanyl (5 μg/kg) and vecuronium 
bromide (0.15 mg/kg), and maintained by intravenous infu-
sion of propofol (150 μg/kg/min) and fentanyl (0.05 μg/kg/
min). In the MF group, anesthesia was induced by intrave-
nous injection of midazolam (0.1 mg/kg), fentanyl (5 μg/kg) 
and vecuronium bromide (0.15 mg/kg), and maintained by 
intravenous infusion of midazolam (1 μg/kg/min) and fen-
tanyl (0.05 μg/kg/min). All patients underwent tracheal in-
tubation and mechanical ventilation. Before splitting stern 
and CPB, patients in the PF group were given propofol (1 
mg/kg) and fentanyl (5 μg/kg) intravenously, while patients 
in the MF group were given midazolam (0.1 mg/kg) and 
fentanyl (5 μg/kg) intravenously.
After heparinization (4 mg/kg), CPB was created. During 
the operation, peripheral oxygen saturation (SPO2), naso-
pharyngeal temperature and rectal temperature were moni-
tored continuously. Heartbeat restoration, time of CPB, 
time of aorta cross-clamp and total operation time were re-
corded.
Post-operative management
After the operation, all patients were admitted to the Inten-
sive Care Unit (ICU) and monitored there. Before being dis-
charged from the ICU, patients were required to meet the fol-
lowing three criteria: 1) conscious; 2) spontaneous breathing 
and removed endotracheal tube; 3) stable hemodynamics 
without vasoactive drugs, or only requiring use of low doses 
of dopamine or dobutamine (less than 5 μg/kg/min). Tracheal 
extubation time and length of ICU stay were recorded.
Biochemical analysis 
Venous blood samples were obtained before operation (T0), 
at 2 h after aorta cross-unclamp (T3), and at 24 h after oper-
ation (T4), for measurement of serum superoxide dismutase 
(SOD) activity and levels of interleukin 6 (IL-6), interleu-
kin 8 (IL-8), and malondialdehyde (MDA). The blood sam-
ples were centrifuged at 1,000 g for 15 minutes and the se-
rum samples were stored at - 80°C until analysis.
Serum IL-6 and IL-8 levels were determined by enzyme-
Open-heart surgery is the main treatment strategy for 
congenital heart disease. However, infants undergoing car-
diac surgery for congenital heart disease are at risk for 
myocardial ischemia-reperfusion injury.2 Myocardial isch-
emia in the perioperative period is a major cause of morbid-
ity and mortality after surgery. It is currently estimated that 
congenital heart defect repairs have a 4% mortality rates.3 
Although multiple factors contribute to the pathogenesis 
of myocardial ischemia-reperfusion injury, accumulating 
evidence indicates that inflammation and oxidative stress 
play an important role.4 New evidence suggests that anes-
thetics may be useful in protection against perioperative 
myocardial injury during cardiac surgery. As propofol and 
midazolam have gained widespread use in cardiac surgery, 
their cardioprotective effects have been increasingly recog-
nized. Experimental and clinical studies have demonstrated 
that propofol and midazolam attenuated myocardial isch-
aemia-reperfusion injury.5-7 However, their underlying 
mechanisms are not completely understood, and only limit-
ed information is available regarding the precise effects of 
propofol and midazolam on inflammation and oxidative 
stress.8-10 Furthermore, the relationship between their pro-
tective effects and clinical prognosis has not been investi-
gated in children with congenital heart disease undergoing 
open-heart surgery. Therefore, in this study, we compared 
the effects of propofol and midazolam on inflammation, 
oxidative stress and clinical prognosis, and investigated the 
underlying mechanisms of these effects.
MATERIALS AND METHODS
Study subjects 
After institutional approval and written, informed parental 
consent, thirty-two ASA class I-II children, aged 3-14 
years, undergoing cardiopulmonary bypass (CPB) for con-
genital heart diseases, were randomly divided into two 
groups: propofol combined with low dose fentanyl (PF 
group, n = 16) and midazolam combined with low dose 
fentanyl (MF group, n = 16). The thirty-two congenital 
heart diseases included tetralogy of fallot (8 cases), transpo-
sition of the great arteries (4 cases), single ventricle (4 cas-
es), pulmonary stenosis (4 cases), trilogy of fallot (3 cases), 
tricuspid atresia (3 cases), total anomalous pulmonary ve-
nous drainage (3 cases), pulmonary atresia with atrial septal 
defect (2 cases) and Ebstein’s malformation (1 case). Pa-
tients with liver or renal dysfunction, hemostatic disorders Wen-fang Xia, et al.
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tive expression). Five random fields per section were ana-
lyzed to produce a single number for the section.
Statistical analysis
Categorical variables were expressed as percentages and 
continuous variables as mean ± standard deviation. Differ-
ences between categorical variables were assessed using t 
test. The χ2 test was used to analyze differences between 
categorical variables. Data were analyzed using SPSS for 
windows version 11.0 (SPSS Inc., Chicago, IL, USA). A p 
value < 0.05 was considered significant.
RESULTS
Clinical characteristics
Clinical characteristics are summarized in Table 1. The age, 
sex, weight, height, preoperative left ventricular ejection 
fraction, total time of CPB, time of aorta cross-clamp, naso-
pharyngeal temperature, and ratio of heartbeat restoration 
showed no significant difference between the two groups. 
However, tracheal extubation time and length of ICU stay 
in the PF group were significantly shorter than those of the 
MF group (p < 0.05, respectively).
IL-6 and IL-8 levels
Changes in IL-6 and IL-8 levels are shown in Fig. 1. Com-
pared with T0, IL-6 and IL-8 levels were significantly in-
creased at T3 and T4 in both groups (p < 0.05, respectively). 
However, the PF group exhibited lower IL-6 and IL-8 levels 
at T3 and T4 than the MF group (p < 0.05, respectively).
linked immunosorbent assay (ELISA) with the results pre-
sented with in units of pg/mL. All procedures were done 
according to the instructions provided with the kits from 
Biosource International, Camarillo, CA, USA.
Serum MDA levels were measured by the thiobarbituric 
acid reagent method with the results presented in units of 
nmol/mL. Serum SOD activity was detected by the method 
of the xanthine oxidase with the results presented in units of 
U/mL. All procedures were done according to the instruc-
tions provided with the kits from Jiancheng Bioengineering 
Research Institute, Nanjing, China.
Immunohistochemical staining
Myocardial samples from the right ventricular outflow tract 
were collected 10-20 min after aorta cross-clamp (T1) and 10-
20 min after aorta cross-unclamp (T2), and were then fixed in 
10% neutral buffered formalin. Formalin-fixed myocardial 
tissues were embedded in paraffin and cut into 5 μm sections.
For the measurement of heme oxygenase-1 (HO-1) ex-
pression, the sections were incubated with primary antibody 
(rabbit polyclonal antibody against human HO-1 from Boster 
biological technology, Wuhan, China)(1 : 1,000) at 4°C over-
night. Incubation with the secondary antibody (goat anti-rab-
bit IgG antibody also from Boster biological technology, 
Wuhan, China) was performed at 37°C for 30 min. Staining 
was generated with the DAB kit from Boster biological tech-
nology, Wuhan, China. Sections were viewed with at 400 × 
magnification and the intensity of HO-1 staining was ana-
lyzed using computer-assisted morphometry by HIPAS-2000 
(Champion image, Wuhan, China) and presented with aver-
age gray value (the larger the gray value, the lower the posi-
Table 1. Clinical Characteristics
PF group (n = 16) MF group (n = 16)
Male / Female 11 / 5 9 / 7
Age (yrs)   6.57 ± 7.66   7.14 ± 5.82
Height (cm) 102.28 ± 30.41 113.25 ± 33.41
Weight (kg)   18.25 ± 13.29   22.28 ± 14.40
Preoperative LVEF (%) 59.56 ± 1.31 60.69 ± 2.09
The total time of CPB (min)   64.00 ± 11.41 60.00 ± 8.25
The time of aorta cross-clamp (min) 34.69 ± 7.24 36.06 ± 5.67
Nasopharyngeal temperature (°C) 24.58 ± 2.53 25.75 ± 1.68
Ratio of heart beating restoration (%) 87.5 100
Tracheal extubation time (hrs)   14.17 ± 7.40* 23.65 ± 8.82
ICU staying time (hrs)   30.17 ± 8.33*   49.47 ± 10.22
LVEF, left ventricular ejection fraction; CPB, cardiopulmonary bypass; ICU, Intensive Care Unit; PF, propofol combined with low dose fen-
tanyl; MF, midazolam combined with low dose fentanyl.
Data are shown as mean ± SD or n (%). 
*p < 0.05 vs. group MF.Propofol and Midazolam in Cardiac Surgery
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DISCUSSION
The main findings of our study are that propofol is superior 
to midazolam in reducing inflammation and oxidase stress. 
Propofol is preferable to midazolam in improving post-op-
eration recovery in children with congenital heart disease 
undergoing open-heart surgery. Propofol’ exerting of stron-
ger protective effects than midazolam may be related to its 
stimulating more HO-1 expression.
It has been shown that inflammation and oxidase stress 
are central to cardiac ischemic and reperfusion injury. Mul-
tiple basic studies and clinical trials have demonstrated that 
inflammation and oxidase stress levels increased during 
myocardial ischemia and reperfusion.11-14 In the present 
study, we found that MDA levels increased and SOD levels 
decreased after CPB. This suggests that ischemic and reper-
SOD and MDA levels
Changes in SOD and MDA levels are shown in Fig. 2. Com-
pared with T0, the MDA level was significantly increased, 
but the SOD level was significantly decreased at T3 and T4 in 
both groups (p < 0.05, respectively). However, the PF group 
exhibited lower MDA and higher SOD levels at T3 and T4 
than the MF group (p < 0.05, respectively).
HO-1 expression
The average gray value is shown in Table 2. The larger the 
gray value, the lower the positive expression. Thus, the ex-
pression of HO-1 at T1 was significantly lower than at T2 in 
both groups (p < 0.05, respectively). However, the HO-1 
expression in the MF group was significantly lower than in 
the PF group at all the corresponding time points (p < 0.05, 
respectively). Fig. 3 shows representative sections at T1 and 
T2 from the two groups.
Fig. 1. Comparison of the effects of propofol and midazolam on serum IL-6 and IL-8 levels. Data are shown as mean ± SD. *p < 0.05 vs. T0. 
†p < 0.05 vs. group MF. IL-6, interleukin 6; PF, propofol combined with low dose fentanyl; MF, midazolam combined with low dose fentanyl.
Fig. 2. Comparison of the effects of propofol and midazolam on serum SOD and MDA levels. Data are shown as mean ± SD. *p < 0.05 vs. 
T0. †p < 0.05 vs. group MF. SOD, superoxide dismutase; MDA, malondialdehyde; PF, propofol combined with low dose fentanyl; MF, mid-
azolam combined with low dose fentanyl.
Table 2. Comparison of Gray Scale of HO-1 Expression in the Two Groups
Time point PF group (n = 16) MF group (n = 16)
T1  182.24 ± 0.77† 193.52 ± 1.37
T2    125.64 ± 2.07*,†   145.46 ± 7.41*
HO-1, heme oxygenase-1; PF, propofol combined with low dose fentanyl; MF, midazolam combined with low dose fentanyl.
Data are shown as mean ± SD.
*p < 0.05 vs. T1. 
†p < 0.05 vs. group MF.
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ventricular function, Corcoran, et al.6 reported that propofol 
attenuated systemic inflammation during elective coronary 
artery bypass grafting. In addition, An, et al.18 reported that 
propofol can inhibit the increase of plasma levels of IL-8, 
MDA and the respiratory index, and attenuate pulmonary 
inflammatory response and dysfunction induced by CPB.
Midazolam was also proven to exert anti-inflammatory ef-
fects. It was suggested that benzodiazepines inhibit murine 
phagocyte oxidative metabolism and production of IL-1, 
tumor necrosis factor-alpha (TNF-α) and IL-6.19 Several 
studies have found that midazolam inhibits human neutro-
phil function and the activation of human umbilical vein 
endothelial cells induced by TNF-α in vitro.20,21 Kim, et al.9 
further discovered that midazolam exerted anti-inflammato-
ry action by inhibiting inducible nitric oxide synthase and 
cyclooxygenase-2 expression, possibly through the sup-
pression of NF-kappaB and p38 mitogen-activated protein 
kinase activation. In the present study, we further compared 
the anti-inflammatory effects of propofol and midazolam, 
and found that PF groups exhibited lower IL-6 and IL-8 lev-
els at T3 and T4 than MF groups. The results of the present 
study indicate that propofol has greater potential to reduce 
inflammation than midazolam.
HO-1 is an inducible stress-response protein that imparts 
fusion injury increase oxidase stress levels. 
Both propofol and midazolam are known to have poten-
tial anti-inflammatory effects and antioxidant activity.8-10 
They have been proven to provide protective effects for pa-
tients underwent cardiac surgery. In the present study, we 
also found that propofol is preferable to midazolam in im-
proving post-operation recovery in children with congenital 
heart disease undergoing open-heart surgery.
Propofol has a structure similar to phenol-based scaven-
gers such as the endogenous antioxidant vitamin E. In isch-
emic reperfused isolated rat hearts, propofol was found to 
be protective against peroxidative damage and functional 
impairment induced by ischemia-reperfusion.15 In patients 
who underwent coronary artery bypass grafting surgery, 
propofol was demonstrated to attenuate myocardial lipid 
peroxidation.16 As a benzodiazepine derivative, midazolam 
was also proven to exert some antioxidant activity. Howev-
er, it has been demonstrated that propofol has greater poten-
tial to reduce oxidative stress than midazolam.17 Our results 
are in accordance with this viewpoint. The results from the 
present study showed that PF groups exhibited lower MDA 
and higher SOD levels at T3 and T4 than MF groups. 
Apart from antioxidant activity, propofol is known to in-
hibit the inflammatory response. In patients with impaired 
Fig. 3. Examples of immunohistochemical staining of myocardial HO-1 expression (brown)(Magnification, 400×). (A and C) Myocardial 
HO-1 expression at T1 and T2 in MF group, respectively. (B and D) Myocardial HO-1 expression at T1 and T2 in PF group, respectively. HO-1, 
heme oxygenase-1; PF, propofol combined with low dose fentanyl; MF, midazolam combined with low dose fentanyl.
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4. Steffens S, Montecucco F, Mach F. The inflammatory response as 
a target to reduce myocardial ischaemia and reperfusion injury. 
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reperfusion in rats: effects on 15-F2t-isoprostane formation. Can J 
Physiol Pharmacol 2003;81:14-21.
6. Corcoran TB, Engel A, Sakamoto H, O’Shea A, O’Callaghan-En-
right S, Shorten GD. The effects of propofol on neutrophil func-
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coronary artery bypass grafting in patients with impaired ventricu-
lar function. Br J Anaesth 2006;97:825-31.
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biomechanical parameters during heart perfusion and after mid-
azolam pre-medication--experimental pilot study. Biomed Pap 
Med Fac Univ Palacky Olomouc Czech Repub 2008;152:79-82.
8. Chen RM, Chen TG, Chen TL, Lin LL, Chang CC, Chang HC, et 
al. Anti-inflammatory and antioxidative effects of propofol on li-
popolysaccharide-activated macrophages. Ann N Y Acad Sci 
2005;1042:262-71.
9. Kim SN, Son SC, Lee SM, Kim CS, Yoo DG, Lee SK, et al. Mid-
azolam inhibits proinflammatory mediators in the lipopolysaccha-
ride-activated macrophage. Anesthesiology 2006;105:105-10.
10. Kang MY, Tsuchiya M, Packer L, Manabe M. In vitro study on 
antioxidant potential of various drugs used in the perioperative pe-
riod. Acta Anaesthesiol Scand 1998;42:4-12.
11. Arumugam TV, Okun E, Tang SC, Thundyil J, Taylor SM, Wood-
ruff TM. Toll-like receptors in ischemia-reperfusion injury. Shock 
2009;32:4-16.
12. Blancke F, Claeys MJ, Jorens P, Vermeiren G, Bosmans J, Wuyts 
FL, et al. Systemic inflammation and reperfusion injury in patients 
with acute myocardial infarction. Mediators Inflamm 2005;2005: 
385-9.
13. Ji L, Fu F, Zhang L, Liu W, Cai X, Zhang L, et al. Insulin attenu-
ates myocardial ischemia/reperfusion injury via reducing oxida-
tive/nitrative stress. Am J Physiol Endocrinol Metab 2010;298: 
E871-80.
14. Prabhu A, Sujatha DI, Kanagarajan N, Vijayalakshmi MA, Ninan 
B. Effect of N-acetylcysteine in attenuating ischemic reperfusion 
injury in patients undergoing coronary artery bypass grafting with 
cardiopulmonary bypass. Ann Vasc Surg 2009;23:645-51.
15. Kokita N, Hara A, Abiko Y, Arakawa J, Hashizume H, Namiki A. 
Propofol improves functional and metabolic recovery in ischemic 
reperfused isolated rat hearts. Anesth Analg 1998;86:252-8.
16. De La Cruz JP, Zanca A, Carmona JA, de la Cuesta FS. The effect 
of propofol on oxidative stress in platelets from surgical patients. 
Anesth Analg 1999;89:1050-5.
17. Tsuchiya M, Asada A, Maeda K, Ueda Y, Sato EF, Shindo M, et 
al. Propofol versus midazolam regarding their antioxidant activi-
ties. Am J Respir Crit Care Med 2001;163:26-31.
18. An K, Shu H, Huang W, Huang X, Xu M, Yang L, et al. Effects of 
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antioxidant and anti-inflammatory effects. HO-1 is highly in-
duced by agents and chemicals producing oxidative cellular 
stress including endotoxin, hydrogen peroxide, hypoxia, and 
hyperoxia.22 It has been demonstrated that HO enzyme activ-
ity degrades heme to biliverdin, carbon monoxide (CO), and 
Fe2+. Biliverdin is reduced to bilirubin. Biliverdin and bili-
rubin scavenge reactive oxygen species and inhibit comple-
ment activation and leukocyte infiltration. CO provides an-
ti-inflammatory and anti-apoptotic effects via p38 MAPK 
activation.23 These findings suggest that HO has both anti-
inflammatory and anti-oxidant potential. HO-1 overexpres-
sion exerts potential cardioprotective functions in ischemia 
reperfusion injury, suggesting that this protein represents an 
endogenous defense mechanism against injury. HO-1 in-
duction by pharmacological agents and genetic engineering 
prevents myocardial ischemia reperfusion injury.24,25 In the 
present study, we found that the PF group exhibited higher 
HO-1 expression than the MF group. This may be an im-
portant mechanism for propofol exerting stronger protec-
tive effects than midazolam. 
This study has at least two limitations. First, we did not 
record postischemic cardiac function or hemodymanic pa-
rameters. Second, post-ischemic proinflammatory and oxi-
dative stress may exacerbate myocardial cellular injury, evi-
denced as increases in troponins or creatine kinase MB. 
However, we did not measure these parameters. Further re-
search is needed to compare these parameters between the 
two groups. 
In conclusion, propofol exerts greater potential to reduce 
inflammation and oxidative stress and to improve post-op-
eration recovery through inducing more HO-1 expression 
than midazolam. Propofol may be preferable to midazolam 
for children with congenital heart disease undergoing open-
heart surgery.
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